Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient.

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprise a solid base which is a water-soluble polymer and/or wax. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. Furthermore, the formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune diseases.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: To provide a pharmaceutical composition comprising a water-insoluble active substance, surfactant(s) and solid carrier(s), which is improved in dissolution and oral absorption characteristics.

Abstract: Provided is a medicinal composition having a very satisfactory drug release profile and a very satisfactory drug absorption profile after oral administration characterized by its comprising an insoluble drug and two or more surfactants, at least one of the surfactants having as dissolved therein the insoluble drug and the other surfactant or surfactants.

Abstract: An off-road vehicle is equipped with an endless articulated steel band drive system including a drive wheel, a plurality of idle wheels and an endless belt extending around the drive wheel and the idle wheel. A back slider plate extends along the inner surface of the endless belt to urge the ground contact surface of the endless belt against the ground. The leading portion of the back plate rises upwardly at an angle of with respect to the ground. One of the idle wheels is rotatably mounted to the rear end of the back plate and the back plate is mounted to the vehicle frame by a leaf spring.

Abstract: A saddle-type vehicle for operation on irregular and uneven ground, wherein a pair of rear suspension arm assemblies each connected pivotally to the rear part of a main frame of the vehicle. The assemblies have suspension arm portions connected operatively at their middle points to the lower end of a shock absorber, and rear end portions disposed at a higher and/or inner position than front end portion thereof. The main frame has a pair of lower tubes connected rigidly with a corresponding pair of upper tubes by way of connecting members. The pair of lower tubes are formed at their midway portions to provide holding members for the front end portions of the suspension and these holding members are directed in the same direction as swing axes for the suspension assemblies.

Abstract: An improved two cycle engine is disclosed which includes a subchamber which is in communication with the exhaust port with a cylindrical valve rotatably disposed therebetween. A reed valve unit is turnably supported in the inlet port to open and close the latter. The cylindrical valve is operatively connected to the reed valve unit by way of a linkage mechanism. Either of the cylindrical valve and the reed valve unit is actuated by a servomotor and the other one is actuated by the linkage mechanism. The servomotor is controlled with the aid of a control circuit so as to allow the engine to be operated at a predetermined number of revolutions.